Literature DB >> 30725300

Rifaximin for Irritable Bowel Syndrome (IBS) in Gulf War Veterans: Losing the Battle but Winning the War?

Lucinda A Harris1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30725300     DOI： 10.1007/s10620-019-05505-w

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  7 in total

Review 1.  Antibiotics for irritable bowel syndrome: rationale and current evidence.

Authors:  Amit H Sachdev; Mark Pimentel
Journal:  Curr Gastroenterol Rep       Date:  2012-10

2.  Double-Blind Placebo-Controlled Study of Rifaximin and Lactulose Hydrogen Breath Test in Gulf War Veterans with Irritable Bowel Syndrome.

Authors:  Ashok K Tuteja; Nicholas J Talley; Gregory J Stoddard; G Nicholas Verne
Journal:  Dig Dis Sci       Date:  2018-10-28       Impact factor: 3.199

3.  Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects.

Authors:  Mark Pimentel; Walter Morales; Ali Rezaie; Emily Marsh; Anthony Lembo; James Mirocha; Daniel A Leffler; Zachary Marsh; Stacy Weitsman; Kathleen S Chua; Gillian M Barlow; Enoch Bortey; William Forbes; Allen Yu; Christopher Chang
Journal:  PLoS One       Date:  2015-05-13       Impact factor: 3.240

4.  Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus.

Authors:  Ali Rezaie; Michelle Buresi; Anthony Lembo; Henry Lin; Richard McCallum; Satish Rao; Max Schmulson; Miguel Valdovinos; Salam Zakko; Mark Pimentel
Journal:  Am J Gastroenterol       Date:  2017-03-21       Impact factor: 10.864

5.  Pathogen-specific risk of chronic gastrointestinal disorders following bacterial causes of foodborne illness.

Authors:  Chad K Porter; Daniel Choi; Brooks Cash; Mark Pimentel; Joseph Murray; Larissa May; Mark S Riddle
Journal:  BMC Gastroenterol       Date:  2013-03-08       Impact factor: 3.067

6.  Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials.

Authors:  P Schoenfeld; M Pimentel; L Chang; A Lembo; W D Chey; J Yu; C Paterson; E Bortey; W P Forbes
Journal:  Aliment Pharmacol Ther       Date:  2014-04-03       Impact factor: 8.171

7.  Effects of Rifaximin on Transit, Permeability, Fecal Microbiome, and Organic Acid Excretion in Irritable Bowel Syndrome.

Authors:  Andrés Acosta; Michael Camilleri; Andrea Shin; Sara Linker Nord; Jessica O'Neill; Amber V Gray; Alan J Lueke; Leslie J Donato; Duane D Burton; Lawrence A Szarka; Alan R Zinsmeister; Pamela L Golden; Anthony Fodor
Journal:  Clin Transl Gastroenterol       Date:  2016-05-26       Impact factor: 4.488
  7 in total
  1 in total

Review 1.  Postinfection Irritable Bowel Syndrome.

Authors:  Uday C Ghoshal
Journal:  Gut Liver       Date:  2022-05-15       Impact factor: 4.519
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.